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Abstract
A major factor in the success of Staphylococcus aureus as a pathogen is its vast arsenal
of virulence determinants and, more importantly, the tight and precisely- timed
regulation of these factors. Here we investigate the product of the S. aureus gene,
SAUSA300_1984,

encoding

a

putative

transmembrane

protein.

This

as

yet

uncharacterized protein belongs to the Abi (abortive infection) family, which are
commonly annotated as CAAX-proteases, and are significantly understudied in
prokaryotes. In S. aureus the disruption of SAUSA300_1984 results in a drastic
reduction of proteolytic and hemolytic activity, as well as diminished pigmentation. This
phenotype appears to be mediated through reduced agr expression, as determined by
qPCR analysis. Importantly, known regulators of agr, such as CodY, MgrA, and ArlR,
demonstrate no significant changes in transcription upon 1984 disruption, whilst major
alterations were observed for downstream effectors of agr, such as sarS, RNAIII, rot
and hla. Complementation and site-directed mutagenesis of 1984 demonstrated that
proteolytic activity (via conserved EE residues) was not required for this phenotype,
suggesting a potential protein-protein interaction mechanism of interaction. Proteome
analysis of the 1984 mutant confirmed a number of our transcriptional observations,
such as an increased abundance of Rot and surface associated proteins, as well as a
marked decrease in Agr-system proteins levels, with the most striking being AgrB.
Virulence profiling revealed a decreased ability of the 1984 mutant to evade
vi

constituents of the innate immune response, and impaired survival during murine
models of infection. Given that SAUSA300_1984 is encoded 3 genes downstream of
RNAIII, our current working hypothesis is that this Abi protein functions to control agr
activity through communication with membrane components of this system, potentially
via interaction with AgrB. Confirming this, and determining the upstream effectors of
this regulatory system are studies currently ongoing in our laboratory.
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Chapter One: Introduction

Staphylococcus aureus
S. aureus is a non-motile, non- spore forming, gram-positive opportunistic pathogen. It
is a facultative anaerobe, and belongs to the phylum of Firmicutes. Firmicutes are
defined by their relatively low guanine and cytosine content in DNA [1]. S. aureus is
comprised of approximately 33% G+C chromosomal content, and has a genome of
approximately 2.8 million base pairs [2]. Staphylococcal disease was first clinically
observed in the early 1880s by Scottish surgeon Alexander Ogston. Ogston described
the bacteria’s role in disease, and more specifically abscess formation and sepsis [3].
Following the examination of pus from a knee joint abscess, he described the presence
of masses that looked like grape bunches; this observation led to the naming of the
bacteria [4]. The etymology behind Staphylococcus is Greek, from the words staphyle,
meaning ‘bunch of grapes,’ and kokkos, meaning ‘berry.’ [4]. Following the
aforementioned discovery of the staphylococcal genus, a German physician, Friedrich
Julius Rosenbach, observed golden colony pigmentation in a staphylococcal strain. The
Latin term for ‘gold’ is aurum, thus, Rosenbach established the binomial nomenclature,

Staphylococcus aureus, in 1884. [4]. The observed golden pigmentation in S. aureus is
a result of a carotenoid, staphyloxanthin [5]. This membrane bound carotenoid holds
antioxidant properties, and is able to protect the bacterial cell from reactive oxygen
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species, and consequently increase virulence [6]. S. aureus can be further identified by
a multitude of biochemical properties, such as the capability of fully lysing red blood
cells and ability to survive in higher salinity [7]. Additionally, this specific species can be
differentiated from other Staphylococci based on its ability to clot human blood as a
result of being coagulase positive [8].

Disease Manifestation in S. aureus
Over 130 years after its discovery, S. aureus continues to be an important pathogen in
human disease. S. aureus can be found as a commensal bacterium in approximate 30%
of the human population’s nasal passages; however, under the right circumstances, it is
capable of causing disease [9]. S. aureus carriers are at higher risk for infection, as well
as Methicillin-resistant Staphylococcus aureus (MRSA) carriers which are estimated to
comprise 2% of the population [9]. S. aureus capable of causing a large array of
infections, which can vary from superficial infections to much more invasive forms that
can lead to death. Skin and soft-tissue infections (SSTIs), are very commonly attributed
to S. aureus, in addition to endocarditis, pneumonia, osteomyelitis, and sepsis [10].
Preferred areas of S. aureus colonization include mucosal membranes and the skin of
humans. However, the bacterium is able to infiltrate the bloodstream, following trauma
and exposure in these areas. Skin to skin contact between a healthy and infected or
colonized individual is the leading mode of transmission for S. aureus infections [11].
Recently, the emergence of community-acquired methicillin-resistant Staphylococcus

aureus (CA-MRSA) has lead to a major increase in SSTIs, and leads to difficulty
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recovering due to resistance. Additionally, the success S. aureus demonstrates in biofilm
formation makes it a large problem in colonization of indwelling medical devices, such
as stents and pacemakers

Treatment for S. aureus infections varies greatly amongst SSTIs, and the
aforementioned invasive infections. Clinicians must be capable of distinguishing
amongst SSTIs, and must able to discern when an infection is more complicated and
will require a more aggressive approach [10]. If mistreated, superficial infections may
progress, spread, and lead to bacteremia. Uncomplicated SSTIs are considered those
that are not accompanied by signs of systemic infection, for example fever. These
infections can be treated by drainage and oral antibiotic therapy [11].

Antibiotic Resistance in S. aureus
Since the initial development of antibiotics, bacteria have been quick to evolve and gain
resistance; some bacteria however, such as S. aureus, have done so at concerning
rates. Horizontal gene transfer plays a major role in the growth of antibiotic resistance
in bacteria [12]. Penicillin was first discovered in 1928 by Alexander Fleming and was
first used on a patient in the early 1940s. This antibiotic began to be noted as the
“miracle drug,” after observing a significant drop in mortality from previously fatal
infections, and consequently igniting the ‘era of antibiotics’ [9]. However, a few years
later cases of resistance began to arise, and by the late 1960s, more than 80% of
isolates from S. aureus infections were resistant to penicillin [13]. Similarly, a β3

lactamase resistance drug, methicillin, was first introduced in 1959 in order to treat S.

aureus infections, which had previously shown this resistance to penicillin [14]. By
1961, cases of methicillin resistance in S. aureus, had emerged, and shortly could be
found across the globe. From this point on, MRSA continued to grow as a problem as it
gained resistance to new therapeutic initiatives attempts at treating infection, and it can
now be considered an epidemic problem [13].

Antibiotic resistance in S. aureus has been described to occur in four different waves
following its emergence. The initial wave (wave 1) was initiated by the emergence of
penicillin as a treatment and subsequent resistance, and extends to present day [9].
This wave continues to this day as more therapeutics are being introduced, followed by

S. aureus acquiring resistance. Wave 2 occurred following the introduction of
methicillin, and thus introducing this new resistant strain, containing mecI, a

staphylococcal chromosome cassette [9]. The mid 1970s started wave 3, which
introduced the emergence of new MRSA strains containing additional staphylococcal
chromosomal cassettes, such as mecII and mecII, which contributed to the ongoing
pandemic in healthcare settings [9]. Lastly, the mid 1990s marked the emergence of
community-associated MRSA, and commenced wave 4; a decade later, Vancomycinresistance S. aureus (VRSA) was observed in clinical isolates. As decades have passed,
the burden of antibiotic resistance in S. aureus has continued to rise as well.

4

Hospital Acquired MRSA and Community Acquired MRSA
For many years, MRSA infections were initially linked to patients in healthcare settings
(HA-MRSA), also noted as a nosocomial infection [15]. However, the emergence of
community-acquired MRSA (CA-MRSA) in the 1990s has brought forth infections in
otherwise healthy individuals, and consequently, MRSA has evolved from being an
exclusively healthcare related illness, to a global problem [16, 17]. MRSA infections
have demonstrated a prevalence rate of 80,000 cases per year in the United States,
with a consequent mortality of approximately 11,000 [18]. In many isolates, CA-MRSA
strains have demonstrated an overexpression of agr, leading to the production of even
larger amount of virulence factors, and have therefore become characterized for their
increase in virulence.

Over 20 different genetic lineages of CA-MRSA have been reported worldwide, with five
demonstrating predominance across the globe, of which include, USA400, USA300,
South West Pacific clone, Taiwan clone, and a European clone [17]. USA300 has been
isolated from every continent across the globe, and this can be considered a pandemic
clone [19]. Most reports of CA-MRSA have demonstrated the involvement of the
USA300 clone, and specifically in the United States it is the most prevalent, and most
likely cause of a future epidemic [17]. In study, CA-MRSA strains have demonstrated
higher involvement with SSTIs, while HA-MRSA strains have shown wide involvement in
respiratory and urinary tract infection, which are both widely associated with healthcare
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settings [20]. However CA-MRSA has the capacity of causing major and lethal
infections, such as fatal brain abscess and bacteremia.

Global Relevance of MRSA
Outbreaks and epidemics of CA-MRSA have been observed across the globe, making S.

aureus an important cause of human disease worldwide. Morbidity and mortality
associated with MRSA continues to rise, and parallel, the financial burden on healthcare
systems rises as well [21]. This is an especially pertinent issue when discussing
countries across the globe with limited resources. In addition to the identified
intercontinental presence of MRSA, clonal lineages are being identified in different
geographic regions [21].

The United States, alongside many important countries in the Americas, such as Brazil,
are demonstrating a prevalence of HA-MRSA of 50% or higher [16]. In South America,
majority of countries demonstrate a prevalence of over 50%, and the remaining 2550%. Additionally, Eastern and southeastern Asia demonstrate very high prevalence at
50% or higher in very large countries such as Vietnam, Thailand, Japan, Taiwan, and
South Korea [16]. Also, Pacific island countries such as Papua New Guinea, Philippines
Indonesia and Australia demonstrate high prevalence ranging from 25-50% [16].
Interestingly, considering the high population rates observed in many countries of
Africa, only a few demonstrate prevalence of 25-50%, for example South Africa, Egypt,
and Algeria; however, many rates are unknown and are most likely a result of
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underreporting [16]. European countries demonstrate a large distribution of prevalence,
ranging from less than 1% in countries such as Iceland and Norway, to over 50% in
Malta. Portugal, Greece, and Italy demonstrate intermediate rates; however they are at
the upper limit of the 25-50% category. In contrast, Spain, Ireland and the UK are at
the lower limit of the 25-50% range [16].

Over the past decades, MRSA rates have continued to rise rapidly worldwide. Although
MRSA has been mostly observed as an endemic problem in healthcare settings, the
emergence of CA-MRSA along with its spread has made MRSA into a greater problem. It
has altered global epidemiology by increasing prevalence rates in countries, which
previously had low rates, and this is of dire concern to public health [16]. To make
matters worse, this epidemiological change is accompanied by the aforementioned
increase in antibiotic resistance. Combined, these two issues bring forth terrifying
scenarios of epidemics and pandemics, where treatment would be complicated due to
the variety in clones emerging worldwide, and their resistance to common antibiotic
therapies.

Virulence Factors in S. aureus
Pathogenicity in S. aureus is very diverse and highly modulated, with various
possibilities depending on surrounding environment and circumstances. The pathogen
produces a wide array of extracellular and cell wall proteins at different stages of
infection in order to optimize its existence and goals [22]. For example, when the
7

bacteria are in the early stages of colonization, they will produce different proteins in
comparison to when they are in stages of dissemination; this coordination is facilitated
by notable global regulators of gene expression in S. aureus [22]. During earlier phases
of growth, such as the exponential growth phase, adhesive, tissue-binding proteins are
actively synthesized, which play a role in colonization of the host [22]. In contrast, in
post-exponential growth phase, these cell wall proteins are repressed, whilst
extracellular toxins and enzymes are actively produced in order to facilitate invasion and
dissemination through the bloodstream [22].

Exotoxins are a very common and important tool in the large arsenal of virulence
factors in S. aureus. These toxins play a role in fighting the cells involved in host
immune response, for example, leukocidins, such as Panton-Valentine Leukocidin (PVL),
are responsible for killing polymorphonuclear (PMN) leukocytes, such as neutrophils and
mononuclear macrophages. These toxins are noted as pore-forming toxins, which lead
to lysis of these eukaryotic cells [23]. The lysis of leukocytes leads to further tissue
damage in the host, due to the leakage of ROS and other oxidizing agents, this holding
an important role in SSTIs and necrotizing disease [23]. Additionally, the four
hemolysins (α, β, γ, δ) are capable of lysing erythrocytes, additionally, some
hemolysins, such as α-toxin contribute to the development of specific diseases such as
skin infections and necrotizing pneumonia [24, 25]. Another toxin, involved in toxic
shock syndrome (TSST-1), is capable of causing cellular destruction of endothelial cells,
and is a major component in disease [26]. Enterotoxins play a leading in food-borne
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disease involving S. aureus; Staphylococcal enterotoxins are the second most common
cause of food-borne illnesses, which potentially lead to hospitalization [27, 28].

S. aureus has ten secreted proteolytic enzymes, also noted as extracellular proteases
[29]. These 10 extracellular enzymes include 6 serine-like proteases (splABCDEF), 2
cysteine proteases staphopain A and staphopain B, 1 V8 serine protease, of which the
other six are homologs, and 1 metalloprotease, aureolysin [29]. These extracellular
proteases are explained to play an important role in virulence, and more specifically in
regulated attachment of bacteria within the host. Biofilms are communities of bacteria
that are very well structured, and which play a major role in S. aureus infection, and
more specifically are heavily observed in nosocomial infection [30]. In S. aureus
extracellular proteases hold an important role in biofilm formation and dispersal from
biofilms. Proteolytic enzymes are very important in the ability for S. aureus to transition
from adhesive motives that demonstrate increased attachment, such as in biofilms, to a
disseminating phenotype in order to further spread infection [30]. For example, these
extracellular proteases can cleave specific host proteins, such as fibrinogen and
fibronectin, and ultimately allowing the bacteria to propagate and spread. These
proteases are also capable of cleaving the heavy chains of immunoglobulins in human
hosts, which can then deter opsonization and elongate bacterial survival within the host
[29]. In addition to modifying host proteins, extracellular proteases also play an
important role n the modification of self proteins. Notably, many surface proteins, such
as protein A and clumping factor B are cleaved by extracellular proteins, SspA and Aur
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respectively, in order to facilitate the aforementioned transition of phenotypes [29].
Along with their role in adhesion, extracellular proteases also play a role in modulating
the abundance of virulence factors at any given time point. Aureolysin for example
plays a role in the tempering of phenol soluble modulins and alpha-toxin [29].

In addition, S. aureus has other important enzymes, such as hyalurinidase, coagulase,
catalase, and fibrinolysin. Hyalurinidase has a role in tissue invasion, this enzyme
hydrolyzes hyaluronic acid, which is a major constituent of the extracellular matrix
(ECM) found amongst eukaryotic cells, notably endothelial cells [31]. Hyaluronic acid is
a viscous substance, which can protect from pathogen invasion. Following its
degradation tissue is exposed to bacterial infiltration and can lead to spread of disease.
Coagulase aids in the conversion of soluble fibrinogen (Factor I) to insoluble fibrin
(Factor IA), a more stable form which is involved in the clotting process in blood [32].
Lastly, catalase is an enzyme involved in the reduction of hydrogen peroxide, and
ultimately aids in the survival of S. aureus from attacks involving oxidants [33].

Surface proteins play a crucial role in S. aureus virulence as well; many are also noted
as microbial surface components recognizing adhesive matrix molecules (MSCRAMMs)
[22]. Some MSCRAMMs include protein A, clumping factor A, extracellular- fibrinogen
binding protein, and fibronectin- binding protein [34]. These proteins play a very
important role in evasion of the innate immune system and survival. For example,
surface associated protein A is capable of binding host immunoglobulins in order to
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prevent opsonization, and furthermore is capable of degrading the immunoglobulin
[35]. Additionally, extracellular fibrinogen binding protein (Efb) plays a role in
interfering with activation of the host complement response by binding directly to C3b,
the activating binding protein [36]. Furthermore, clumping factor can blocks C3b which
has already successfully bound to the bacterial cell, and by doing so prevent the further
cascade brought forth by the complement system[37].

As previously noted, the golden color observed in S. aureus is a result of a carotenoid
pigments found within the organism. This pigment is regulated by complex pathways of
biosynthesis, which produce a wide variety of carotenoids. Many carotenoids can be
found in fruits and vegetables, such as carrots for example, that are known to be
beneficial due to their antioxidant properties, and ability to reduce free-radical species
[6]. Similarly, this pigmentation has shown to be a protective mechanism for S. aureus,
which leads to the ability to evade oxidant-based elimination that is commonly observed
as a mechanism in innate host immunity [6].

Phagocytic leukocytes play a large role in the innate immune response of a host, and
many of their mechanisms are a result of using reactive oxygen species (ROS) following
phagocytosis of pathogen. In abundance, these molecules lead to pathogen death,
however carotenoid presence and therefore pigmentation can act as a protective
mechanism for the bacteria and can result in phagocyte survival [6]. Mutants that
disrupt carotenogenesis have demonstrated impairment in survival following exposure
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to neutrophils, increased sensitivity to oxidants, and decreased pathogenicity in vivo
[6].

The pigment found in S. aureus is termed staphyloxanthin; it is found to function as an
antioxidant, and is reliant on a crt operon, which contains a SigB-dependent promoter
[5]. Biosynthesis of staphyloxanthin is initiated by the condensation of two molecules,
which together form dehydrosqualene; this reaction is catalyzed by CrtM, a
dehydrosqualene synthase [5]. CrtN, a dehydrosqualene desaturase, forms the yellow
intermediate, 4.4’ -diaponeurosporene, via dehydrogenation. The terminal methyl group
of this intermediate is then oxidized by CrtP, a diaponeurosporene oxidase, resulting in
4,4’- diaponeurosporenic acid [5]. Next, the glucose at the C1’’ position is esterified by
CrtQ, a glycosyl transferase, and yields 4,4’-diapponeurosporenoate. Lastly, CrtO, an
acyl transferase, esterifies the glucose on the C6’’ and yields staphyloxanthin [5].

agr Quorum-Sensing System and Virulence Regulation
The agr quorum sensing system is a global regulator of S. aureus virulence. The agr
quorum sensing system is made up of two transcriptional units, RNAII and RNAIII.
Each, transcript contains its respective promoter P2 and P3, respectively; RNAII is the

agr operon, which is comprised of four genes (agrBDCA), upstream of RNAIII, a
regulatory RNA [38]. As a quorum sensing system, regulation is dependent on cell
density, which triggers a signal peptide to initiate autoregulation of the system [38].

12

The signal peptide in the agr system is noted as autoinducing peptide (AIP), and is a
derivative of AgrD. AgrD is a polypeptide, which following proteolytic cleavage by AgrB,
a multifunctional endopeptidase that also acts as a chaperone, results in the thiolactone
AIP signaling peptide [39].

This signaling peptide in an optimal environment binds

AgrC, the membrane sensor in a two-component regulatory system (TCS) [40]. Binding
leads to cross-phosphorylation of AgrC and dimerization of the protein. AgrC then
proceeds to phosphorylate AgrC, the cytoplasmic transcription factor (TF) response
regulator in this TCS. Upon activation, AgrA directly binds the aforementioned P2 and
P3 promoters, and accordingly upregulates the RNAII (agr) and RNAIII expression, as a
positive feedback loop [38]. RNAIII subsequently acts on a large array of genes to
modulate their expression, these genes are highly involved in virulence if S. aureus,
thus explaining the crucial role of agr in S. aureus pathogenesis.

In addition to the agr/RNAIII regulon, other regulators and transcription factors have
an important role in virulence gene expression, and act in both agr-dependent and agrindependent ways. For example, SaeRS is another major TCS that is involved in global
regulation of virulence gene expression [41]. Like many TCSs, SaeRS is widely affected
by external stimuli, such as glucose, pH, and salt levels [42]. In this system, SaeS is the
sensor for these environmental signals, and SaeR provides the response to these cues
by upregulating specific virulence genes [18]. Additionally, the promoter for sae is also
sensitive to signals resulting from exposure to phagocytes, such as increases in
antimicrobial peptides or increases it ROS.
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ArlSR is an additional TCS of S. aureus that holds a role in autolysis, and potentially a
role in cell growth and division. Additionally, the arl system demonstrates involvement
in the downregulation of certain virulence genes, such as coagulase and protein A [43].
The arl system is also able to downregulate RNAII transcription, leading to decreased
expression of RNAIII and agr targeted genes during specific growth phases. Similarly,
CodY is a global regulator in S. aureus, which is involved in metabolism, and is most
expressed during nutrient excess [18]. CodY regulates over 200 genes, ranging from
genes involved in metabolite biosynthesis to virulence, and more specifically agr. CodY
has demonstrated involvement with the regulation of agr by preventing premature
activation of the system during exponential growth phase [18].

The Sar protein family is comprised by another set of important global regulators in S.
aureus. SarA is a DNA-binding protein that has a very important role in gene regulation,
as well as agr expression. SarA is capable of directly binding the divergent agr
promoters, P2 and P3, which consequently can lead to upregulation of the two
transcriptional units [18]. SarA can also function independently from agr by directly
binding promoters in many virulence associated genes [43]. Additionally, many of its
homologues, such as SarT, SarX, and Rot have also been identified for their roles in
virulence factor expression. SarT is an activator of SarS, which when expressed can
lead to the upregulation of protein A and repression of α-toxin [44]. SarX has been
shown as a negative regulator of agr, which can be activated by another homolog
MgrA. Similarly, Rot represses toxin synthesis and upregulates surface attachment
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protein expression, acting opposite of agr [44]. MgrA, another SarA homolog, has
demonstrated its ability to upregulate about 175 genes and downregulate 180 [44].
MgrA is a DNA-binding protein, containing a helix-turn-helix (HTH) motif, observed in
numerous Sar family proteins [45]. Mutations in MgrA have demonstrated an alteration
in virulence factor production, for example, production of protein A and hemolysins
[46].

Alternative sigma factors, such as sigma factor B (SigB), demonstrate a role in the
response to environmental stimuli, for example during waves of stress or energy
depletion [42]. SigB has been shown to control the expression of numerous accessory
genes, and has also displayed recognition of at least 23 different promoters of S. aureus
genes. It has demonstrated involvement in modulation of aggregation by increasing the
expression of adhesin proteins, such as clumping factor [43]. SigB has also proven to
play a role in the pigmentation of S. aureus, leading to increased protection from
oxidant and radiation.

Abi-Domain Protein Family
SAUSA300_1984 is a member of a large family of proteins, containing a conserved Abi
(abortive infection) domain [47]. These proteins are majorly noted as CaaX amino
terminal proteases involved in bacteriocin self- immunity; protease activity is implied by
the role of Abi proteins in eukaryotes [48, 49]. Type II CaaX proteases are involved in
post-translational modification in eukaryotic cells through a mechanism known as
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prenylation, however this mechanisms has not been widely investigated in prokaryotes
[48]. CaaX prenyl proteases in eukaryotes cleave the ‘aaX’ motif of a protein, followed
by the addition of an isoprenoid on the remaining cysteine residue from the previous
CaaX (C-cysteine, A- aliphatic amino acid, A- aliphatic amino acid, X- any amino acid)
motif [47]. This CaaX protease family contains conserved amino acids across bacterial
species and eukaryotes [47]. One of the conserved motifs is comprised of a two
glutamic acids, and is noted as the putative catalytic site of the protein ‘EEXXXR’ [48].
The other two conserved motifs include a phenylalanine and histidine ‘FXXXH,’ and an
invariant histidine ‘H’ [48].

In S. aureus, four other genes in addition to the previously stated have been identified
to belong to this family of proteins, SAUSA300_2262 and SAUSA300_1724, demonstrate
the conserved amino residues, whilst SAUSA300_0932 and SAUSA300_2405 don’t
possess any conserved amino residues. Some of these have been investigated in a S.

aureus Newman background, and have demonstrated a potential role in the trafficking
of YSIRK/G-S signal peptides, or possible contributions to cell division [50]. In these
studies, a SAUSA300_1984 homolog demonstrated a dissimilar role from the
abovementioned, thus it did not follow the novel characterizations for altering cell
surface proteins [50].

In a study investigating an Abi domain protein in Group B Streptococcus, it was
demonstrated that the conserved proteolytic site does not play an essential role in the
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proteins’ function, and rather the Abi protein interacted with a histidine kinase
sensor/response regulator system, CovSR [51]. The Abi domain protein Abx1 was
shown to be a regulator of the CovS histidine kinase sensor in GBS [47]. The
demonstration that the Abi protein acts as a cellular regulator in GBS is a novel finding
in bacterial studies [47]. Abi proteins in prokaryotes are becoming increasingly
investigated, and novel findings continue to emerge, characterizing wide array of
behaviors from prenylation, to cellular regulation, and roles in cell division.

Project Aims
The purpose of this study was to initiate the exploration of a previously uncharacterized
protein. Following a previous screen for novel protease regulators, SAUSA300_1984
demonstrated noteworthy changes in the bacteria’s phenotype. This change included a
decrease in virulence determinant production, which implied a potential regulatory role
of the 1984 protein. Due to the genes proximity to a global regulator of virulence, agr,
the changes observed in a 1984 transposon mutant are of particular interest. In order
to further characterize this gene and its protein product, transposon mutant strains will
be utilized in transcriptional investigations to compare to wild-type, as well as virulence
assays to determine the potential presence of attenuated virulence in ex vivo models.
In addition, we want to investigate change in the 1984 mutant proteome in comparison
to wild-type, and from here determine potential targets of this protein. In order to
combat growing drug resistance, it is crucial that we begin developing therapeutics that
“disarm” S. aureus, instead of solely killing and ultimately causing the development of
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resistance in the pathogen. Further understanding of this uncharacterized protein can
lead to a better understanding of S. aureus virulence mechanisms, which can then lead
to novel developments in antimicrobial therapeutics.
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Chapter Two: Materials and Methods

Strains, Plasmids, and Primers
All bacterial strains and plasmids utilized in this study are listed in Table 1. All primers
used in cloning and qualitative real time- polymerase chain reaction (qRT-PCR)
throughout this study are listed in Table 2.

Media and Growth Conditions
All media used in this study was prepared with deionized water, and steam autoclaved
at 121°C for a minimum of 30 minutes. Bacterial strains were consistently grown at
37°C shaking at 250 rpm. S. aureus bacterial strains were grown in tryptic soy broth
(TSB) or tryptic soy agar (TSA), and E. coli bacterial strains lysogeny broth (LB) or LB
agar. Some investigations required the use of antibiotics for selection; they were added
in

the

following

concentrations

for

S.

aureus:

Spectinomycin,

Erythromycin,

Tetracycline, and Chloramphenicol were all used at a concentration of 5 µg/ml, with the
exemption of Lincomycin at a concentration of 25 µg/ml; some E. coli strains required
ampicillin, which was used at a concentration of 100 µg/ml. Synchronization techniques
were utilized in this study in order to obtain bacterial cultures at a specific growth
phase. In order to do so, overnight cultures were subcultured into fresh media using a
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1:100 dilution factor. Some experiment required the standardization of bacterial
cultures to an OD600 of 0.05.

Table 1. Strains and Plasmids
Organism

Strain

Marker

E. coli

DH5α

N/A

S. aureus

RN4220

N/A

S. aureus

USA300 LAC WT

N/A

S. aureus

USA300 LAC 1984::Tn

E/L

S. aureus

USA300 LAC 1984::Tn::spc

S

S. aureus

USA300 LAC 1984::Tn hla-lacZ:tet

T

S. aureus

USA300 LAC 1984::Tn hla-lacZ:tet

T

S. aureus

USA300 LAC aur-lacZ:tet

T

S. aureus

USA300 LAC 1984::Tn aur-lacZ:tet

T

S. aureus

USA300 LAC rot::tet

T

S. aureus

USA300 LAC 1984::Tn rot::tet

T

S. aureus

USA300 LAC 1984::Tn pSPC

C

S. aureus

USA300 LAC 1984::Tn::spc

S

S. aureus

USA300 LAC agr-lacZ:ery

E/L

S. aureus

USA300 LAC 1984::Tn::spc agr-lacZ:ery

E/L/S

E. coli

DH5α pJB67::1984::Tn::Spc Native Complement

A

E. coli

DH5α pJB67::1984::Tn::Spc Native 6His Complement

A

E. coli

DH5α pJB67::1984::Tn::Spc Non-Native Site Directed Mutant
Complement

A

S. aureus

RN4220 pJB67::1984::Tn::Spc Native Complement

E/L

S. aureus

RN4220 pJB67::1984::Tn::Spc Native 6His Complement

E/L

S. aureus

RN4220 pJB67::1984::Tn::Spc Non-Native Site Directed Mutant
Complement

E/L

S. aureus

USA300 LAC pJB67::1984::Tn::Spc Native Complement

E/L/S
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Table 1. (Continued)
Organism

Strain

Marker

S. aureus

USA300 LAC pJB67::1984::Tn::Spc Native 6His Complement

E/L/S

S. aureus

USA300 LAC pJB67::1984::Tn::Spc Non-Native Site Directed Mutant
Complement

E/L/S

Plasmid

pSPC

C, S

Plasmid

pJB67

A, E

*List of bacterial strain and plasmids utilized throughout this study. Markers depict
antibiotic selection: S- spectinomycin; T- tetracycline; C- chloramphenicol; Eerythromycin; L- lincomycin; A- ampicillin. Tn indicates the insertion of a transposon in
the gene.

Table 2. Primer Sequences
Primer

Sequence

Description

OL 2123

GAGTTGTTATCAATGGTCAC

F sarA qPCR

OL 2124

ACTGCTTTAACAACTTGTGG

R sarA qPCR

OL 2495

AACAATCGGATTTAGTACAG

F sarS qPCR

OL 2496

GTAAGTATTACGCTCATCAA

R sarS qPCR

OL 2536

AGTTTGCCACGTATCTT

F agrB qPCR

OL 2537

TTAGCTAAGACCTGCATC

R agrB qPCR

OL 2538

TTAGTCCAAGGGAACTC

F sarR qPCR

OL 2539

CAAACGACAGTTGTTCA

R sarR qPCR

OL 2540

TTAAGGAAGGAGTGATTTC

F hld qPCR

OL 2541

GTTCACTGTGTCGATAAT

R hld qPCR

OL 3166

CGCGAACGAGAAATCATACAATG

F sigB qPCR

OL 3167

TCTCTGAAGTCGTGATACATGC

R sigB qPCR

OL 3612

GGTCCTTTATTAGCAGCATATGTATTCAG

F 1984 Internal

OL 3613

CTGAATACATATGCTGCTAATAAAGGACC

R 1984 Internal

OL 3777

ATGgaattcTTAGTGGTGGTGGTGGTGGTGTGGAATAAAAATGTGATAT
ATAAAATTCGC

R 1984 6His Tag
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Table 2. (Continued)
Primer

Sequence

Description

OL 4009

AAAGGCAATTTGCCAGATGC

F ccpA qPCR

OL 4010

AATTGCTTCTTCGTCGCTGATAC

R ccpA qPCR

OL 4011

CTAGGTGAATATGCTGCTACAG

F codY qPCR

OL 4012

CCATTGTAATAGCAGCTTTATCG

R codY qPCR

OL 4034

CAGCGAGATTGAAAGCGAATAC

F rot qPCR

OL 4045

CTGTCCATTTCTTTAAGCGTCATAG

R rot qPCR

OL 4036

GGCTCTATGAAAGCAGCAGATA

F hla qPCR

OL 4037

CTGTAGCGAAGTCTGGTGAAA

R hla qPCR

OL 4047

GCTCAAAGACAAGTTAATCGCTAC

F mgrA qPCR

OL 4048

CGTTTACAGGAGATTCATCCCA

R mgrA qPCR

OL 4049

CAAAGTTGCTGGGCTTGATTAC

F arlR qPCR

OL 4050

TTTGTGGCTGACGACGTAAA

R arlR qPCR

OL 4051

TTCGAACACGTGAAGAGAAAGA

F sarZ qPCR

OL 4052

CTGATGCTTCTCGTTCTGAAATG

R sarZ qPCR

OL 4053

CGGTAAAGAATTGAGGGATACATTACAT

F sarV qPCR

OL 4054

CTTGTCTTTCATCCGTTTCAGAAC

R sarV qPCR

OL 4055

CGATGAAGCATTGCAAAGATGA

F sarX qPCR

OL 4056

GTCCTACTTAAATCTAGCTCATCCA

R sarX qPCR

OL 4093

GGCAGATAATGATGATCGC

F pJB67 MCS

OL 4094

CATGTCAACGATAATACAAAATATAATAC

R pJB67 MCS

OL 4139

ATGcccgggATGACAAGATTATGGGCATCATTGC

F 1984 External

OL 4140

ATGgaattcCATGCTATTCTTATTTGTAAAGCGAAATAAAAA

R 1984 External

*List of primer sequences utilized in this study. Restriction sites are noted by underlined
lowercase letters. Site-directed mutagenesis for SOE and his-tag addition is noted in
bold.
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Buffers
PBS
0.8% Sodium Chloride
0.14% Disodium Phosphate
0.02% Potassium Chloride
0.02% Potassium Dihydrogen Phosphate
Solution at a pH of 7.4
Phage Buffer
1M Magnesium Sulfate
4mM Calcium Chloride
50 mM Tris-HCl at a pH of 7.8
5g/L of Sodium Chloride
1g/L of Gelatin

UDS Buffer
6 M Urea
50 mM Tris-HCl at a pH of 8
5 mM DTT
1% SDS

TE Buffer
10 mM Tris-HCl at a pH of 8
1 mM EDTA
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Bacterial Constructs
Native Complement
A native 1984 complement strain was created, in addition to a histidine tagged strain,
due to the putative membrane location of the 1984 protein. In order to create the
complement strain, OL 4139 containing a SmaI restriction site, and OL 4140 containing
an EcoRI restriction site were used to amplify a fragment containing the 1984 gene via
PCR. The resulting 1984 fragment was cloned into the multiple cloning site of pJB67, a
plasmid with a CdCl2 inducible promoter. The constructs where then transformed into E.

coli, and confirmed prior to transforming by electroporation into the S. aureus cloning
strain RN4220. Following, a phage lysate was created using phi 11 bacteriophage
(Φ11), this was subsequently transduced into the LAC USA300 1984 mutant strain for
complementation, and subsequently confirmed via DNA sequencing.

Non-Native Catalytic Site Mutant Complement
Site directed mutagenesis was performed through the use of overlap extension PCR. In
addition to the previously stated external primers, OL 4139 and OL 4140, internal
primers containing a nucleotide mutation for the putative catalytic site, OL 3612 and OL
3613 were also utilized. With the internal primers, two separate fragments were
amplified containing a ‘GCA-GCA’ alteration from the original ‘GAA-GAA’, in order to
substitute the double glutamic acid catalytic site in the protein, for an inactive double
alanine site. PCR amplification using the external forward primer paired with the
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internal reverse primer, in addition to the internal forward primer paired with the
external reverse primer provided the two necessary fragments two create the site
directed mutant complement of 1984. These two separate fragments were then
amplified through PCR without any primers; this step allowed for the two fragments to
anneal and create one whole fragment. Following the fragment was amplified once
more through PCR, however this time the external primers OL 4139 and OL 4140 were
included. This fragment was then cloned into the multiple cloning site of pJB67, a
plasmid with a CdCl2 inducible promoter. Following plasmid cloning, the construct was
transformed into E.coli, and positive colonies were confirmed by sequencing. Plasmid
was then isolated and electroporation was used to transform into the S. aureus cloning
strain, RN4220. Following, a phage lysate was made using Φ11 bacteriophage, and
transduced into the LAC USA300 1984 mutant strain for complementation. The nonnative site directed mutant complement strain was confirmed via DNA sequencing.

Native His-Tagged Complement
Similarly to the native complement, a fragment was amplified with OL 4139 forward
primer containing a SmaI restriction site, and OL 3777 containing a EcoRI restriction
site and the respective nucleotide sequences encoding for histidine prior to the stop
codon, which when translated results in a 6 histidine tag at the proteins C-terminus.
The resulting 1984-His6 fragment was then cloned into the multiple cloning site of
pJB67, a plasmid with a CdCl2 inducible promoter. The constructs where then
transformed into E. coli, and confirmed prior to transforming by electroporation in S.
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aureus cloning strain RN4220. A phage lysate was then made with Φ11 bacteriophage,
and transduced into the LAC USA300 1984 mutant strain for complementation. Lastly,
the his-tagged complement strain was confirmed via DNA sequencing.

Transcriptional Assays
Reporter Gene Fusions
The hla-lacZ, aur-lacZ, and agr-lacZ fusions were all previously constructed using
plasmid pAZ106. As a result, the only necessary steps were to create phage lysates
from host strain using Φ11 bacteriophage, and transduce each phage lysate into both
the wild-type and 1984 mutant strains. Following transduction, DNA was extracted from
final bacterial strain containing the new fusion, and confirm via PCR. Once strains were
confirmed, TSA plates containing X-gal substrate were used to observe transcript levels
for the genes of interest.

Quantitative Real Time-PCR
mRNA was isolated from wild-type and the 1984 mutant cultures which had been
synchronized to exponential growth phase. Cultures were synchronized in 5 ml volumes,
to which 5 ml of cold sterile PBS was added. The cultures were then centrifuged at
2,843 x g for 10 min, the supernatant was removed, and the remaining bacterial pellet
was frozen overnight in the -80°C freezer. The bacterial pellets were resuspended in
100 µl of TE buffer, and processed with glass beads in a Mini BeadBeater for 40
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seconds. Following lysis, 700 µl of β-mercaptoethanol (BME) was added, followed by
700 µl of RLT buffer. The samples were processed once more on the Mini BeadBeater
for 40 seconds, followed by centrifugation at 17,000 x g for 2 seconds to burst bubbles.
After centrifugation, 600 µl of the supernatant were collected into a new tube, and 900
µl of 100% ethanol were added. Samples were then transferred to RNeasy spin
columns, and treated with 350 µl of RWI buffer. The columns were then washed with
500 µl of RPE buffer, and samples were eluted with 50 µl RNase-free water. Eluted
samples were then treated with DNase enzyme at 37°C for 40 minutes. Using the
iScript cDNA synthesis kit, cDNA was synthesized for the RNA samples, and PCR
confirmed. Following, qRT-PCR was performed utilizing sybr green polymerase, and 20
µl reactions. Reactions were performed in technical duplicates for each biological
replicate; 16s rRNA was used as a control. Investigated genes included: rot, sigB, sarR,

sarS, sarV, sarX, sarZ, agrB, hla, hld, sarA, codY, ccpA, arlR, and mgrA, respective
primers are listed in table 2.

Protein Assays
Protein Extraction
Following the growth of an overnight culture in biological triplicate, and subsequent
synchronization to exponential growth phase, 1 ml of wild-type, 1984 mutant and agr
mutant strain cultures were centrifuged, and the pellets resuspended in 300 µl of PBS.
These samples were then treated with 10 µl of Lysostaphin at 37°C for 1 hour in a
waterbath to allow lysis. Samples were then treated with 5 µl of DNAse I enzyme at
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37°C for 1 hour in a waterbath. Samples were then centrifuged at 17,000 x g for 10
minutes, at which point the supernatant was transferred into a new tube and labeled as
the cytoplasmic fraction, and the pellet was resuspended in 100 µl of UDS buffer and
labeled as the membrane fraction. Samples for the two fractions were then quantified
for protein concentrations utilizing a Pierce 600 nm protein assay kit.

Protein Digestion
Proteins were treated with reducing buffer in order to induce denaturation. The samples
were loaded on FASP spin columns, following the addition of 100 µl of Urea buffer, and
centrifuged at 14,000 x g for 5 minutes. This wash step was repeated with 200 µl of
Urea buffer, followed by the additional of 100 µl IAA buffer and light vortexing. The
samples were then allowed to alkylate in the dark for 20 minutes, centrifuged at 14,000
x g for 5 minutes, and removed of any flow through. Samples were then washed with
100 µl Urea Buffer and centrifuged a total of three times. A total of, 100 µl of TEAB
buffer was then added to the column, centrifuged at 14,000 x g for 5 minutes, and
repeated 3 times. The filters were then transferred to new tubes and eluted. Trypsin
was mixed into TEAB buffer at a 1:50 ratio, and added to the protein for digestion.
Samples were incubated in a humidified 37°C incubator overnight.

Desalt
C18 MacroSpin columns were activated using 500 µl of 100% acetonitrile, followed by
centrifugation at 1,100 x g for 2 minutes. Flow through was discarded, and the exterior
28

of the column was blotted dry. MacroSpin columns were then equilibrated by adding
500 µl of 0.1% formic acid and centrifuging at the aforementioned speed and time,
followed by the removal of flow through, for a total of 2 times. Following equilibration,
the columns were ready for the addition of protein samples. Samples were added,
centrifuged, and the flow through was removed from the collection tube. Samples were
washed twice more with 0.1% formic acid, centrifuged, and removed of flow through in
order to ensure salts and solvents were no longer present in the column. Once
complete, the retained protein samples were eluted using 500 µl of 100% acetonitrile,
and placed in a new, low-binding collection tube. Samples were then vacuum dried
using SpeedVac centrifugation, and store at 4°C until ready for peptide quantification
and MS analysis.

Label-Free Mass Spectrometry
Prior to analysis through mass spectrometry, proteins samples were digested, and
peptides quantified with a Pierce 460 nm peptide assay kit. Samples were run on a
hybrid linear ion trap (LTQ Orbitrap XL) mass spectrometer and protein informatics
software (MaxQuant and Scaffold) was used. Protein intensities were averaged and
compared to wild-type to determine fold changes in the mutant strains. Welch’s t test
and a cut off of ≥ 1.5 change were used to determine statistical significance of proteins
changes.
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Virulence Assays
Human Whole Blood Survival Assay
Overnight bacterial cultures were grown in biological triplicate for wild-type, 1984
complement, 1984 mutant, agr mutant, and the hla mutant strains. They were
synchronized to exponential growth phase. Cultures were then washed three times in
PBS, and standardized to an OD600 of 0.05 in PBS. The necessary volume was then
calculated for each culture, and used to inoculate 1ml of whole human blood purchased
from BioreclamationIVT. A sample was obtained at hour 0, and the blood cultures were
then incubated at 37°C on a rotator for 4 hours. Samples were taken at hour 4, diluted
to 10-6, and plated on TSA in technical duplicate to percent recovery from initial inocula.

THP-1 Macrophage Infection Assay
THP-1 human monocyte cells were acquired and properly seeded into a flask containing
RPMI medium supplemented with L-glutamine, 10% fetal bovine serum, and 1%
penicillin/streptomycin solution; cells were grown at 37°C in a 5% CO2 environment
throughout. Once the cells reached a confluence of at least 80%, viable cells were
counted using Trypan blue dye and a C-chip. Using the number of cells counted on the
C-chip, a density was appointed, and a standard volume was used which contained 106
cells per well, and these cells were spun down and resuspended in the aforementioned
RPMI media, however also treated with 80 nM PMA (phorbol 12-myristate acetate) to
induce differentiation and attachment. Six well plates were seeded with the treated
cells, and the cells were incubated at 37°C in a 5% CO2 environment for 48 hours to
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allow for differentiation and well adherence. Bacterial cultures were standardized to an
OD600 of 0.05, and opsonized in 20% human sera at 37°C for 30 min. Differentiated
macrophage cells were then washed with PBS, and infected with an MOI of 1 this was
done with wild-type, 1984 mutant, and agr mutant strains in the aforementioned cell
media sans antibiotic treatment. Plates were centrifuged at 450 x g for 10 minutes, and
phagocytosis was allowed to proceed for 1 hour at 37°C in 5% CO2. Following bacterial
uptake, cells were washed with PBS and treated with 30 µg/ml of gentamicin in FBS
supplemented RPMI media for an additional hour at 37°C in 5% CO2 in order to kill
remaining extracellular bacteria. To quantify bacterial cells phagocytosed, eukaryotic
cells were washed with PBS, and treated with 1 ml of 0.5% Triton X-100 in order to
cause lysis. Lysates were then diluted and plated on TSA in technical duplicates in order
to determine the percent phagocytosed. In order to calculate intracellular survival, the
experiment was performed as abovementioned; however instead of lysing after
treatment with 30 µg/ml gentamicin, cells were washed and treated with media
containing 5 µg/ml gentamicin, and allowed to proceed for no more than 24 hours at
37°C in a 5% CO2. Following this final incubation, cells were lysed as previously
described, followed by lysate dilution and plating on TSA in technical duplicate. CFU/ml
obtained from this process was then compared to the percent phagocytosed, and
intracellular survival was concluded.
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Chapter Three: Results

Exploration and Phenotypic Identification of 1984 as a Virulence
Determinant in Staphylococcus aureus
SAUSA300_1984 became a gene interest following exploration of uncharacterized genes
in the S. aureus genome. The specific gene was located 3.8 kb upstream of the wellstudied agr operon (Fig. 1). Upon further investigation, this gene was noted to encode
a protein that belongs to an Abi-domain family, with a theoretical role that suggested a
function that is understudied in prokaryotes. This family of proteins is majority
comprised of CaaX proteases, which in eukaryotes are involved in a process known as
prenylation. Prenylation is a form of post-translational modification, and these proteases
are ultimately involved in the modification of proteins in order to facilitate cell
membrane anchoring.

To date, five genes in the S. aureus genome belonging to this Abi-domain family
(PF02517) of CaaX proteases have been previously characterized in our lab. This study
has

been

completed

through

the

utilization

of

transposon

mutants.

Upon

characterization, one of these five genes, SAUSA300_1984, demonstrated a pleiotropic
effect following disruption of the gene by transposon insertion. Analysis on 5% sheep
blood agar demonstrated a significant decrease of hemolytic activity in the 1984 mutant
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when compared to the wild-type strain, indicating that disruption of the 1984 gene in
the mutant leads to a decrease in hemolysin production (Fig. 2A). Additionally, analysis
on casein agar revealed a similar trend. Examination of proteolytic activity in the 1984
mutant demonstrated a reduced zone of clearing, indicating a decrease in protease
production when compared to the wild-type strain (Fig. 2B).

Figure 1. Close Proximity of SAUSA300_1984 to agr Operon Suggests
Potential Regulatory Role. Through analysis of the S. aureus genome,
SAUSA300_1984 was discovered to be an uncharacterized gene located upstream of the
well-studied agr operon. Considering the major role agr has in the regulation of
virulence determinant production, the investigation of this uncharacterized gene was of
interest. The close proximity to this major regulatory operon suggests a potential role in
virulence factor regulation.
With consideration of these substantial changes in hemolysin and protease production,
the 1984 mutant was examined for potential growth deficit. The 1984 mutant strain
was grown overnight in TSB alongside the wild-type strain. Testing for statistical
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significance demonstrated no change in growth potential between the wild-type and
mutant strain (Fig.3). Observations suggested that the 1984 protein plays a role in S.

aureus pathogenicity, through regulation of virulence determinant production.

Figure 2. The 1984 Mutant Demonstrates an Altered Phenotype with Changes
in Virulence Factor Production. A side by side comparison of LAC wild-type strain
(right) and the LAC 1984 mutant strain (left). Bacterial strains were plated on sheep
blood agar in order to observe changes in hemolysis (A), and casein nutrient agar to
observe changes in proteolysis (B).

Bioinformatic Analysis of 1984 as a Member of the Abi Protein Family
Utilizing

bioinformatics

allowed

for

further

study

of

the

uncharacterized

SAUSA300_1984 gene. Investigation of the Abi family led to the finding of a highly
conserved ‘Glu-Glu’ motif, which has been identified as the putative catalytic site for this
family of proteins (Fig. 4A). As previously mentioned, majority of the members in this
Abi protein family function through a proteolytic mechanism. Thus, the next step was to
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investigate the role of the conserved Glu-Glu motif in the function of the 1984 protein.
Protein visualization sources depict five transmembrane helices, two cytoplasmic loops,
and two smaller extracellular loops. The cytoplasmic loop nearest the C-terminus
contains the two glutamic acids, which constitute the hypothetical catalytic site (Fig.
4B).

Figure 3. The 1984 Mutant Strain Displays No Deficit in Growth When
Compared to the Wild-Type Strain. Wild-type, 1984 mutant, and agr mutant strains
were grown to exponential phase, and separately inoculated into TSB with a starting
OD of 0.05. This was performed in biological triplicate and technical duplicate, and
optical densities were taken every 2 hours. A student’s T-test with Welch’s correction
demonstrated no statistical significance between wild-type and the mutant strains. Error
bars are shown in ± SEM.
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Figure 4. Bioinformatic Analysis Demonstrates a Conserved Hypothetical
Catalytic Site in the Abi Family of Proteins and Hypothetical Protein
Topology. An HMM logo obtained through bioinformatics illustrates the highly
conserved Glu-Glu residue in the Abi family of proteins, these residues comprise the
putative catalytic site. The role of this catalytic site was investigated through the use of
alanine scanning. The two glutamic acid residues were substituted by two alanine
residues, as shown in the wild-type and mutant amino acid sequence (A). Cellular
location of the Glu141 and Glu142 residues was emphasized with hypothetical protein
topology obtained through bioinformatics (B).
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Alanine scanning is a technique that allows for the substitution of amino residues of
interest with a chemically inert, and significantly smaller amino acid, alanine. Through
the use of site-directed mutagenesis and overlap extension PCR (OE-PCR), a non-native
mutant complement was constructed by substituting the two glutamic acid residues
encoded by ‘GCA-GCA’ in the catalytic site for two alanine residues encoded by ‘GAAGAA’ (Fig. 4A). Subsequent to confirmation by DNA sequencing, the non-native 1984
site-directed mutant was tested for hemolytic activity on sheep blood agar, alongside
the native complement constructs (Fig. 5 C-D), wild-type (Fig. 5E), and the 1984
mutant (Fig. 5A) strains. Hemolytic activity was restored in the native complement
constructs (Fig. 5C-D), as well as the non-native site-directed mutant complement (Fig.
5B).

A

B

C

D

E

Figure 5. Site-Directed Mutagenesis of the 1984 Catalytic Site Negates the
Theoretical Role as a Protease. Following site-directed mutagenesis and
complementation of the 1984 gene, it is determined that the protein encoded by
SAUSA300_1984 is not functioning through a proteolytic mechanism. Hemolytic activity
is demonstrated on sheep blood agar. The 1984 mutant (A) illustrates the
aforementioned decrease in hemolysis, and the non-native site-directed mutant
complement (B), native his-tagged complement (C), native complement (D), and wildtype (E) strains demonstrate normal or restored hemolytic activity.
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The restoration of this virulence factor in the site-directed mutant indicates that the
catalytic site does not play a major role in 1984 protein function; 1984 does not
function through a proteolytic mechanism, rather it functions via protein-protein
interaction.

Transcriptional Studies Given the Suggested Influence of 1984 on Virulence
Determinant Production
Following the observed changes in hemolysin and protease activity in the 1984 mutant,
transcriptional analysis proceeded through the use of reporter gene fusions. Two genes
of interest, hla (α-toxin) and aur (metalloprotease aureolysin) had been previously
constructed in our lab in the form of lacZ fusions. Each fusion, hla-lacZ and aur-lacZ
was transduced into the appropriate wild-type strain (USA300 LAC) and into the 1984
mutant strain. In order to analyze transcription of α-toxin and the metalloprotease
aureolysin, the bacterial strains containing the lacZ fusions were plated on TSA
containing a colorless lactose analog, X-gal. Upon transcription of the lacZ gene, and
ultimate translation of the protein the gene encodes for β-galactosidase, interaction
with this colorless substrate results in the production of blue pigmentation in the
bacteria. This is a result of a reaction in which the substrate, X-gal, undergoes
hydrolysis facilitated by the active enzyme β-galactosidase. Upon hydrolysis and
spontaneous oxidation, the substrate produces a blue insoluble product, 5-5’-dibromo4-4’-dichloro-indigo. This blue product allows for the qualitative visualization of
transcription. By observing a difference in blue pigmentation, one can discern a
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decrease or increase of transcription in the gene of interest. When comparing transcript
levels of hla in the 1984 mutant, there is an evident decrease, which is suggested by
the decrease in blue product (Fig. 6A). A similar trend is illustrated when comparing
transcription of aur in the 1984 mutant (Fig. 6B). The changes that occur as a result of
the mutation of 1984 can now be described to be occurring at a transcriptional level.

Considering agr is a major regulator of these virulence determinants, the next step was
to investigate potential changes in transcript level of agr in the 1984 mutant. Through
the same technique, an agr-lacZ fusion was transduced into the wild-type and 1984
mutant strains. These bacterial strains were plated on TSA containing the necessary
substrate x-gal, and the production of blue pigment was observed. The 1984 mutant
strain containing the agr-lacZ fusion demonstrated a drastic difference in the production
of blue pigmentation, and therefore the transcription of agr. In comparison to normal
production in the wild-type strain, the 1984 mutant seems to contain minimal to no blue
pigmentation in the bacteria (Fig. 7). Thus, it was concluded that not only does 1984
hold a role in the production of virulence factors, but it is modulating the transcription
of agr. Interestingly, within the two sample fractions, multiple proteins were found in
common between the 1984 mutant and the agr mutant.
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Figure 6. Analysis with Reporter Fusions Demonstrates a Transcriptional
Decrease of Two Known Virulence Factors in the 1984 Mutant. A side by side
comparison of LAC wild-type strain (right of divider line) and the LAC 1984 mutant
strain (left of divider line). Bacterial strains containing hla-lacZ (A) and aur-lacZ (B)
reporter fusions were plated on TSA containing a colorless substrate X-gal (IUPAC: 5bromo-4-chloro-3-indolyl-β-D-galactopyranoside). Presence of blue pigment is indicative
of β-galactosidase enzymatic activity, which corresponds to transcription of the lacZ
reporter gene within the fusion.
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Figure 7. Analysis with a Reporter Fusion Demonstrates a Decrease in
Transcription of agr in the 1984 Mutant. A comparison between Wild-type strain
(Right of divider) and the 1984 mutant (Left of divider) containing an agr-lacZ reporter
fusion. These reporter fusion strains were plated on TSA containing a colorless
substrate X-gal (IUPAC: 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside). Presence
of blue pigment is indicative of β-galactosidase enzymatic activity, which corresponds to
transcription of the lacZ reporter gene within the fusion.

Role of 1984 on Other Known Regulators and Effectors of Staphylococcus

aureus
To further investigate the role of 1984 as a modulator of transcription, (qRT-PCR) was
conducted with an array of gene targets. qRT-PCR analysis was conducted for both
wild-type and the 1984 mutant strains, in biological triplicates and technical duplicates.
The 16s rRNA gene was utilized to normalize the raw data, and mutant values were
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standardized to wild-type. To begin this exploration, transcription of agrB, RNAIII, and

hla were quantitatively analyzed. A highly significant decrease was noted for the three
genes (Fig. 8A) Transcriptional levels of agrB demonstrated a 13.8-fold decrease in the

1984 mutant. Additionally, as demonstrated with the use of an hla-lacZ fusion in the
1984 mutant, qRT-PCR determined 14.8- fold decrease in the transcriptional level of hla
in the mutant strain. The most profound change in transcription was noted in the
transcript levels of RNAIII, where a 201-fold decrease was observed in the 1984
mutant. Transcription of RNAIII is directly regulated by agr activity. Thus, a decrease in

agr activity, along with another very important transcriptional regulator, rot, elicits this
severe decrease in transcript level. The acquisition of this data confirms the
transcriptional changes in agr, in a further quantitative manner than the initial
investigation with lacZ fusions.

Following the validation of decreased agr transcription, multiple known regulators of agr
were examined. Regulators arlR, mgrA, codY, and ccpA have been very well studied for
their role in regulation of virulence factors and agr, thus their study assisted in
determining whether agr is being modulated directly or indirectly by 1984. Upon
analysis by qRT-PCR, these known regulators demonstrated no significant difference of
transcript levels in the 1984 mutant (Fig. 8B).
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Figure 8. Quantitative Real-Time PCR Analysis Including Known Regulators
and Effectors of agr Demonstrates Noteworthy Alterations of Transcription
Levels in the 1984 Mutant. Quantitative real-time PCR analysis was performed on
numerous targets to determine transcriptional changes in known regulators and
effectors of agr, in addition to agr itself. Illustrated is the transcriptional comparison
between USA300 LAC wild-type and the 1984 mutant. The 16s rRNA gene was used to
normalize the data, and wild-type values were used to standardize the date (2-ΔΔCt). All
analysis was performed in biological triplicate and technical duplicate. A student’s T-test
with Welch’s correction was used to determine statistical significance (n.s., p > 0.05; *,
p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001; ****, p ≤ 0.0001), error bars are shown in ±
SEM.
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Some very notable changes in other effectors were also observed following qRT-PCR.
Most notably one specific transcriptional regulator, rot, acts opposite of agr and
demonstrated a significant change in the 1984 mutant. Under normal conditions, agr
upregulates RNAIII transcription, and RNAIII negatively regulates rot (Fig. 9). In the

1984 mutant, we see a reverse in transcript levels with agr and RNAIII showing a
decrease in transcription, there is a significant increase in rot transcript levels (Fig. 8C),
specifically a 4.6-fold increase. This change further indicates the direct effect of 1984
has on agr, and reinforces the certainty of the role in virulence determinant production.
Additionally, sarA, demonstrated a 2.4-fold decrease in transcription in the 1984
mutant. Other notable SarA homologs were also investigated and displayed significant
changes in transcript levels: sarR a 2.6-fold increase, sarS a 10.9-fold increase, sarV a
4.9-fold increase, sarX a 2.2-fold increase, and sarZ a 6.4-fold increase. In addition,
global regulator, sigB, illustrated a 2.33-fold increase in the 1984 mutant.
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Figure 9. Putative Map Illustrating the Direct Interaction of 1984 on agr and
Other Regulators of Virulence Determinants in S. aureus. Following
transcriptional analysis of the 1984 mutant, a hypothetical map of interacting regulators
and effectors was developed. 1984 is believed to directly interact with agr, ultimately
resulting in a downstream effect on virulence factor production.
Proteomic Approach to Determine the Role of 1984 on Protein Production
Noting all of the significant changes seen in the 1984 mutant on a transcriptional level,
it was essential to determine if these changes were also present in the proteome. Using
a proteomic approach, a multitude of changes were noted in the production of proteins
for the 1984 mutant in comparison to wild-type. Proteomic analysis of the cytoplasmic
and membrane fractions was performed on the wild-type, 1984 mutant, and agr mutant
strains. Upon analysis of the raw data, 392 total proteins were identified from the
cytoplasmic fraction. Of these identified proteins, 255 proteins were found in common
between the wild-type and the two mutant strains (Fig. 10A). More notably, out of 542
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total proteins identified in the membrane fraction, 321 were identified to be common
amongst the three strains (Fig. 10B).

Figure 10. Comparison of Identified Proteins Following Proteomic Analysis of
Wild-Type, 1984 Mutant, and agr Mutant Strains. Use of a Venn diagram
illustrates a comparison of proteins identified through proteomic analysis. The
cytoplasmic fraction (A) compares wild-type (Cyto _WT), 1984 (Cyto_1984), and agr
(Cyto_Agr) mutant strains. Similarly, the membrane fraction (B) compares wild-type
(Mem_WT), 1984 (Mem_1984), and agr (Mem_Agr) mutant strains. The center
highlighted in yellow represents common proteins that are found in all of the three
strains. The cytoplasmic fraction illustrated 255 proteins out of 392 total that all three
strains share in common (A). In the membrane fraction, 321 identified proteins out of
542 total proteins are shared by all three strains (B).

Many of the changes seen on a protein level were similar to the trends previously
characterized in the qRT-PCR analysis. Highly notable was the 15.6-fold increase in the
aforementioned repressor of toxins, rot (Table 3), validating the transcriptional studies
above. Changes in the production of Rot protein further imply the alteration of agr and

RNAIII in the 1984 mutant. Another change that further endorses the initial change
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displayed in transcript level is that of AgrB. Protein intensity values for AgrB
demonstrated a 7.9-fold decrease in the 1984 mutant when referenced to wild-type
values (Table 4). Additionally, a new alteration is seen in the production of AgrA
protein, presenting a 2.7-fold decrease of protein intensity in the 1984 mutant (Table
3). This decrease in AgrA and AgrB production suggests the absence of 1984 leads to
an overall decrease in autoregulation within the agr quorum sensing system.

Looking back at the qRT-PCR results from this study, the significant decrease in sarS
can be recalled (Fig. 8C). This change is particularly noteworthy considering the
increase in immunoglobulin G binding protein A (protein A) abundance in the 1984
mutant; protein intensities demonstrated a 21.72-fold increase. Referencing back to
Figure 9, it is understood that sarS is a positive regulator of protein A, and a repressor
of α-toxin. Considering that sarS is an effector of agr, it was no surprise to observe this
significant increase in protein A abundance
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Table 3. Notable Cytoplasmic Protein Fold Change in the 1984 mutant
Protein

Function

Fold Change

HTH-type transcriptional
regulator rot (Rot)

Repressor of toxins; global
regulator

+16.59

HTH-type transcriptional
regulator (SarR)

Regulatory protein which downregulates sarA expression

+1.96

Accessory gene regulator
A (AgrA)

Response regulator in quorum
sensing signal transduction

-2.67

Transcriptional regulator
(SarA)

Transcriptional regulator; Global
regulator of several virulence
factors; Regulator of agr

-1.92

Methicillin resistance
protein (FemA)

Susceptibility towards beta-lactam
antibiotics when inactive; formation
of cell wall peptidoglycan

-2.49

*Interesting protein changes following proteomic analysis of the cytoplasmic fraction

Influence of 1984 on Virulence in Staphylococcus aureus
Considering the significant differences observed in the transcriptional and translational
levels of numerous regulators of virulence, it was necessary to investigate the potential
role of 1984 in S. aureus pathogenicity. The 1984 mutant, agr mutant, hla mutant, wildtype, the 1984 complement strains were studied for their ability to survive and
proliferate in whole human blood. Bacterial strains were grown to exponential phase in
biological triplicate, standardized to an OD600 of 0.05, and were then separately
inoculated into 1 ml of whole human blood. Blood cultures were incubated at 37°C and
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samples were extracted at specific time points through hour 4. Percent recovery was
determined following comparison of CFU/ml following incubation to the initial inocula
(Fig. 11). As expected, the agr mutant demonstrated a significant decrease in ability to
recover in a host environment; agr mutant illustrated 7.8-fold decrease. Furthermore,
the 1984 mutant illustrated an even more pronounced deficit in ability to recovery with
a 14.8-fold decrease. Both the wild-type and hla mutant recovered at 100%, and the
1984 complement demonstrated a 1.4-fold increase, indicating an increased ability to
propagate in human blood (Fig. 11).
Table 4. Notable Membrane Protein Fold Change in the 1984 Mutant
Protein

Function

Fold Change

Accessory gene regulator
B (AgrB)

Involved in the processing of AgrD
propeptide

-7.87

Immunoglobulin G binding
protein A (Spa)

Upregulated by SarS; Promote
biofilm formation

+21.72

Extracellular matrixbinding protein (Ebh)

Promotes bacterial attachment to
soluble and insoluble forms of
fibronectin

-7.40

Immunoglobulin-binding
protein (Sbi)

Interacts with both the adaptive
and innate host immune response

+16.15

Oligopeptide permease,
peptide-binding protein
(opp-1A)

Iron and heme acquisition; role in
infection models

+21.275

*Interesting protein changes following proteomic analysis of the membrane fraction
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Figure 11. Analysis of Bacterial Survival In Whole Human Blood
Demonstrates Deficit in the 1984 Mutant. Bacterial strains were grown in
biological triplicate to exponential growth phase. All strains were standardized to an
OD600 of 0.05, and were separately inoculated into 1 ml of whole human blood. Samples
were taken at specific time points and percent survival was calculated using CFU/ml and
the initial inocula. A student’s t-test was used to determine statistical significance (n.s.,
p > 0.05; *, p < 0.05), error bars are shown in ± SEM.
Following the display of decreased survival ability in a host environment, the 1984
mutant was investigated for its ability to evade the human innate immune response.
THP-1 human macrophage-like cells were used at a 1 x 108 cells/ml. The differentiated
THP-1 cells were infected separately in biological triplicate with 106 CFU/ml of the wildtype, 1984 mutant, and agr mutant strains. Cells were incubated at 37°C with 5% CO2
supplement, and phagocytosis was allowed to proceed for one hour. The macrophage
cells were then treated with gentamicin in order to eliminate remaining extracellular
bacteria. To investigate intracellular bacterial content, the macrophage cells were lysed,
the lysates were serially diluted, and plated on TSA. The percent of bacteria
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phagocytosed was calculated by comparing CFU/ml at hour 1 to the initial inocula (Fig.
12A). The 1984 mutant demonstrates a 1.8- fold increase in the percentage of bacteria
phagocytosed; additionally, the agr mutant showed a 3.4- fold increase in phagocytosis.
This increase in percent phagocytosed indicated that the 1984 mutant was less
successful in evading the phagocytic cells. The agr mutant, as expected, demonstrated
a much more pronounced increase in phagocytosed bacterial cells, and thus, a more
significant decrease in ability to evade the phagocytic cells.

To further investigate the ability to survive in a host immune environment, a further 24hour time point was examined to determine percent survival of the wild-type, 1984
mutant, and agr mutant strains (Fig. 12B). Percent survival of the bacterial cells was
determined by comparing the CFU/ml from hour 1, or phagocytosed cells, to the
CFU/ml from hour 24. Upon analysis, the agr mutant demonstrated a 1.6-fold decrease
in survival, whilst the 1984 mutant demonstrated a 1.5-fold decrease in survival.
Overall, the mutant strains demonstrated a decreased ability to evade the host immune
cells, in addition to a decreased ability to survive once inside the host cell.
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Figure 12. The 1984 Mutant Has Decreased Success in Evading Human Cells
Involved in the Innate Immune Response. THP-1 Human Macrophage cells were
separately infected by each bacterial strain in biological triplicate. Phagocytosis was
allowed to proceed for 1 hour, at which time CFU/ml was compared to initial inocula in
order to determine percent phagocytosed (A). The experiment continued to 24 hours,
at which point final CFU/ml was compared to CFU/ml of hour 1, in order to determine
percent survival within the cells. A student’s t-test was performed to determine
statistical significance (*, p > 0.05), error bars are shown in ± SEM.
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Chapter Four: Discussion

S. aureus demonstrates an extraordinary ability to infect and survive within the host.
This fascinating ability is a result of the pathogens’ large array of virulence factors, and
their intricate regulation [43]. In particular, the agr quorum sensing system has been
widely studied and is considered to be one of the most understood major regulatory
systems in S. aureus virulence [18]. Importantly, complete genome sequencing, in
addition to other resources such as ordered transposon libraries, have facilitated the
identification of previously uncharacterized virulence affecting genes in S. aureus [2,
52]. To this end, we present an exploration of the gene/protein 1984 in this work,
revealing an apparent role in agr regulation.

During our initial investigation of the 1984 transposon mutant, pronounced changes in
two very prominent factors of S. aureus virulence, hemolysins and proteases
demonstrated a very interesting alteration worth further investigating. Phenotypic
characterization of the 1984 mutant demonstrated that the mutant’s ability to lyse
blood cells and the ability to hydrolyze proteins is reduced due to decreased hemolytic
and proteolytic activity, respectively. This pleiotropic effect following the disruption of

1984 by a transposon is indeed notable, and, given the genomic location and close
proximity to the agr operon, these findings provided ample motive for continued
investigation.
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Supplementary investigation of the changes occurring in the 1984 mutant indicates
transcriptional effects on agr, along with α-toxin and metalloprotease aureolysin.
Utilizing lacZ as a reporter gene, we were able to characterize α-toxin and
metalloprotease aureolysin activity on a transcriptional level. By observing the
production of blue pigmentation in the bacteria growth, which corresponds to βgalactosidase enzymatic activity, we infer the transcript levels of the reporter gene,
which in turn corresponds to the transcription of the hla, aur, and agr fusions. The
decrease of blue pigment production in the 1984 hla-lacZ and 1984 aur-lacZ fusions
indicates a significant decrease in transcription of α-toxin and metalloprotease
aureolysin, respectively. Similarly, the 1984 agr-lacZ fusion demonstrates a much more
dramatic decrease in blue pigmentation, indicating a reduction in transcript levels.

Further analysis of transcript levels by qRT-PCR supports the results previously obtained
by the lacZ reporter gene fusions. Quantification confirms a decrease of hla
transcription in the 1984 mutant, validating the qualitative results from initial
transcriptional studies. The first gene in the agr locus (agrBDCA), agrB, was
investigated to further ascertain variations of agr activity between the 1984 mutant and
wild-type. This quantification demonstrated a noteworthy decrease in transcript levels
for agrB; and consequently, analysis of effector, RNAIII, reveals a substantial reduction
of transcript levels in the 1984 mutant. The deviations observed in agrB and RNAIII
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transcription may explain the diminution of virulence determinant production observed
in the 1984 mutant strain [38].

Observing the change in agrB transcription, and prior decrease in virulence factor
production initiated the examination of well-known regulators in order to determine the
possibility of an indirect regulatory effect by 1984. ArlR, the response regulator
alongside ArlS is part of a two-component system, modulates the level of extracellular
AIP, which leads to downregulation of the agr locus, and RNAIII transcription [43].
Similarly, global metabolic sensor and regulator CodY aids the downregulation of agr
transcription under specific conditions [18, 38]. CcpA is another metabolite response
regulator of S. aureus, which has demonstrated a role in the upregulation of RNA III,
and thus virulence factors [18, 53]. Additionally, MgrA has been previously identified as
a global regulator, demonstrating an effect on protein A, α-toxin, and numerous other
virulence factors [46]. Examination of these known regulators using qRT-PCR illustrates
no significant variation in transcript level, and therefore the changes seen in agr
regulation, in addition to virulence factor synthesis, is not the consequence of an
upstream effect resulting from alteration in these regulatory systems.

Additional regulators and effectors were subsequently examined to further unravel the
regulatory effect of 1984 on agr. The Sar family proteins have been widely studied for
their roles in the regulation of agr and virulence factor production [44]. SarA itself is an
activator of virulence genes and acts through agr dependent and independent
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pathways. Analysis by qRT-PCR demonstrated a slight decrease in sarA transcription in
the 1984 mutant. We conclude that this observed change does not account for the
severe changes observed in agr and virulence determinant activity. Additional sarA
homologs that were investigated on a transcriptional level include rot, sarR, sarS, sarV,

sarX, and sarZ. With the exception of sarA, all other homologs in this study
demonstrate a significant increase in transcript levels [44].

One of the most notable differences is an increase in rot, which holds an important role
in the upregulation of cell wall proteins, and downregulation of toxin production; an
opposite role to agr [54]. rot is repressed by RNAIII under normal conditions; however
in the 1984 mutant, a significant increase is observed. Therefore the increase in
transcription of rot in the 1984 mutant further sustains the changes observed in agr
upregulation, and consequent RNAIII regulation. SarS is an effector of SarT, a SarA
homolog which under normal conditions is repressed by both sarA and agr [44].
Additionally, SarS is an activator of spa and repressor of hla. Given the observed
decrease in both sarA and agr transcription in the 1984 mutant, an increase in SarT
activity is expected, and consequently we observe a significant change in the increase
of sarS transcription in the 1984 mutant.

SarR is a DNA-binding protein that has been shown to repress SarA activity by binding
one of the gene’s promoters [44]. In the 1984 mutant we observe a slight increase in
transcription of sarR, which corresponds to the aforementioned decrease seen with
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sarA. SarX, another homolog, is activated by mgrA, which demonstrated no change in
transcript levels. Although no change is observed in mgrA, an increase is seen in sarX
transcription in the 1984 mutant [46]. SarV and SarZ, were the other two SarA
homologs characterized by qRT-PCR. Both sarV and sarZ have been minimally
characterized, however in studies they have demonstrated a potential role in virulence,
eliciting attenuation upon deletion [44]. In the 1984 mutant we see a significant
increase in transcript levels for sarV and sarZ. Given their suggested roles in the
positive regulation of virulence (i.e. hla upregulation) [44] their increase in the 1984
mutant further implies the observed attenuation of virulence displayed is a result of agr
deficit , thus further implying it is the result of a direct interaction with 1984.

Many of the changes seen on a transcriptional level were also observed in the
production of those specific proteins. Following proteomic analysis, numerous
membrane and cytoplasmic proteins were detected to have significant changes in the
1984 mutant. Notable proteins include Rot, SarR, AgrA, and SarA in the cytoplasmic
fraction, and AgrB, Spa, Sbi and ClfA, in the membrane fraction [55]. The
transcriptional changes in rot were also demonstrated on a protein level with changes
that are statistically significant. Additionally, both SarR and SarA demonstrate similar
trends observed following qRT-PCR, in which the proteins demonstrate a slight increase
and decrease, respectively. The slight fold changes observed in SarA and SarR seem to
correspond with each other, a similar relation seen in their transcriptional quantification.
Noting this less than 2-fold change in SarA, suggests that although the protein is being
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affected by the lack of 1984 in the mutant, it is not a result of a direct effect, rather is
likely an indirect effect due to downregulation of the Agr quorum sensing system.
Changes in AgrA are documented for the first time in this study following proteomic
analysis. A negative fold changes observed indicate a decrease in the phosphorylation
of AgrA response, which validates the decrease in agr transcription. Most importantly,
we observe a significant negative fold change of AgrB, a membrane constituent of the
Agr regulatory system involved in the secretion of AIP.

A very important aspect of S. aureus, which leads to success in host colonization via
adherence to the extracellular matrix, includes adhesin proteins, specifically those
belonging to the MSCRAMM family [34]. A significant increase in adhesin proteins, such
as protein A (Spa), Iron-regulated surface determinant protein A (isdA), and
immunoglobulin-binding protein (Sbi), are observed in the 1984 mutant. These proteins
are commonly cleaved by proteases in order to regulate their expression and facilitate
detachment from the cell wall and into a soluble form [56]. Decreases in AIP levels
result in a reduction of agr activity and consequently a decrease in levels of
extracellular proteases, which are necessary for protein cleavage [57]. This increase in
surface proteins can be explained by lowered agr activity in the 1984 mutant. This
increase in surface adhesins can result in increased propensity for biofilm formation, in
addition to an overall attenuation in detachment [30]. This can result in a deficit in the

1984 mutant for dispersal and migration in order to iniitate colonization of new sites for
infection [58].
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The global changes in the 1984 mutant may elicit attenuated virulence as suggested by
the ex vivo investigation. Disruption of the 1984 gene leads to myriad alterations of
virulence regulators, and consequently changes in virulence factor production.

The

1984 mutant demonstrates a deficit in the ability to evade the innate immune response,
and ultimately less success in survival within a host environment[6]. Whole human
blood contains numerous constituents, which together play an important role in the
immune response against bacterial infection, for example lymphocytes, phagocytic
leukocytes, antibodies, and enzymes. Given the role of S. aureus septicemia as a
leading cause of death in S. aureus diagnoses [13], an ex vivo model of sepsis was
used to investigate survival. Following analysis, the 1984 mutant exhibits a deficit in
ability to survive, while the complementation of the 1984 gene using a multi-copy
plasmid demonstrates increased ability to survive and recover in the presence of whole
blood components [59]. The 1984 mutant was also studied alongside an agr mutant, a
non-hemolytic strain, which demonstrates similar defect in survival and recovery. This
loss in ability to thrive within a host environment indicates that the decrease in
regulators and virulence determinant production translates to lowered survival ex vivo.

An additional macrophage infection model was utilized to investigate the host innate
immune response and the pathogenic abilities of the 1984 mutant. Macrophages
attempt to internalize the bacteria in order to eradicate them. However S. aureus has
numerous factors which facilitate evasion of the host cells in addition to survival and
proliferation following phagocytosis [60]. Macrophages, in comparison to neutrophils,
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are long-lived phagocytic cells; they are more likely to play a role in dissemination due
to their migratory nature [60]. To examine survival, a human macrophage cell line was
used, and an agr mutant was utilized as reference. The 1984 mutant demonstrates both
a decrease in ability to evade phagocytosis by macrophages, and a decrease in ability to
survive once internalized by the host cell; these results are similar to those observed in
the agr mutant, although not as severe. This is explained by the decrease in agr and

RNAIII activity in the 1984 mutant. Observed decreases in global regulators of virulence
determinants, such as hemolysins and proteases, leads to attenuated virulence in the

1984 mutant [61].

Proteomic analysis provided further insight into the potential mechanism in which 1984
acts. Changes observed in the protein levels of AgrA and AgrB support the hypothesized
interaction with 1984. Reduction of the cytoplasmic response regulator in the agr
system initiates a decrease in activity due to reduced phosphorylation by the system
sensor, AgrC. This decrease can be the result of decreased production and export of the
necessary autoinducing peptide (AIP), which acts as the auto-activating signal of the
quorum sensing system [62]. The major decrease in protein AgrB, denotes the
aforementioned decrease in AIP levels; given that AgrB is involved in the processing
and secretion of the AgrD peptide, its decrease results in a decrease of AIP, and thus
abated autoregulation of the agr system [63]. Through a mechanism of protein-protein
interaction, we believe that the 1984 membrane protein directly interacts with AgrB.

60

Thus, the absence of 1984 leads to alteration in the quorum sensing system, which
ultimately leads to a diminution in the upregulation of RNAII and RNAIII transcripts.
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Future Directions
Following the aforementioned investigations of the 1984 mutant, we have unraveled
information that has led us closer to the function of this protein, and have acquired
evidence that this protein may in fact be a constituent of the membrane. However, in
order to further elucidate the role of 1984, it is necessary to confirm protein localization
and discern the mechanism behind this newly characterized protein. During the study of

1984, a histidine-tagged native complement was also constructed utilizing the CdCl2
inducible-plasmid. By being able to produce a protein with a 6His tag, it is possible to
purify the tagged protein via an affinity ligand or detect location via anti-His antibodies.
Examination of the secreted, cytoplasmic, and membrane fractions by western blot
analysis will allow for the confirmation of protein location.

To further investigate the mechanism behind 1984, transmembrane protein topology
mapping through the use of a substituted cysteine accessibility method (SCAM ™) [64]
will be performed. Bioinformatics illustrates the hypothetical topology for the 1984
protein containing 5 transmembrane helices. Through modification of the amino acid
sequences in 1984 by introducing cysteine residues to various locations on the protein,
structural relationship of the transmembrane helices can be investigated [64].
Additionally, this technique can lead to differentiation of amino acid residues that are
critical to protein function.
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As we believe that 1984 functions by interacting with a membrane constituent in the

agr system, AgrB, it is necessary to investigate prospective proteins with which it
interacts. Understanding these interactions are crucial to understanding the biological
processes in which 1984 is involved. Utilizing a bacterial two-hybrid system (BTH) will
allow for the investigation of interaction between 1984 and AgrB, or other potential
partners. This method follows a “bait” and “target” technique in which 1984 acts as the
bait, and potential proteins of interaction are the targets [65]. Protein-protein
interaction may be detected following the activation of a reporter gene, for example

lacZ. A clone library for binding partner screening would us closer to deciphering the
regulatory role of 1984 in a complex network [66]. Cross talk amongst regulatory
systems is very common in S. aureus; as a result, it is necessary to elucidate the role of
newly characterized 1984 in virulence gene regulation.

Another point of exploration includes the mechanism behind 1984 activation. In addition
to determining which proteins 1984 interacts with, it is also necessary to determine how
1984 activity is modulated. For example, further investigation could determine whether
1984 is activated as a result of ligand binding, transcription factor binding to DNA, or
direct protein-protein interaction. Nevertheless, it is crucial to understand the regulation
of 1984, in addition to its own novel regulatory roles.
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Appendix
Table A-1. Proteins identified in Proteomic Analysis of Cytoplasmic Fraction

Protein ID

Gene

Fold
change

Q2FEP3

30S ribosomal protein S19 (RpsS)

19.24

A0A0H2XFX7

HTH-type transcriptional regulator rot (Rot)

16.59

Q2FHV1

Iron-regulated surface determinant protein A (IsdA)

15.25

A0A0H2XI52

Uncharacterized protein (1863)

9.435

A0A0H2XJG9

Uncharacterized protein (1684)

5.585

A0A0H2XJH7

Immunoglobulin G binding protein A (Spa)

4.808

Q2FG58

50S ribosomal protein L20 (RplT)

4.227

A0A0H2XGG6

ABC transporter, ATP-binding protein (1285)

3.662

A0A0H2XHU1

Succinate dehydrogenase, flavoprotein subunit (SdhA)

3.323
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Table A-1. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XIK0

Peptide deformylase (Def)

2.464

A0A0H2XH01

Signal recognition particle protein (Ffh)

1.959

Q2FEQ1

50S ribosomal protein L5 (RplE)

1.941

Q2FEN9

50S ribosomal protein L3 (RplC)

1.768

Q2FDQ7

L-lactate dehydrogenase 2 (Ldh2)

1.717

Q2FK29

L-lactate dehydrogenase 1 (Idh1)

-1.360

A0A0H2XEX6

Transcription termination/antitermination protein (NusA)

-1.521

Q2FG31

UPF0173 metal-dependent hydrolase (1653)

-1.557

Q2FI10

Phosphoribosylformylglycinamidine synthase subunit
(PurQ)

-1.599

A0A0H2XGD7

ATP-dependent 6-phosphofructokinase (PfkA)

-1.622

Q2FJM8

Xanthine phosphoribosyltransferase (Xpt)

-1.634
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Table A-1. (Continued)

Protein ID

A0A0H2XIW4

Fold
change

Gene

Probable malate:quinone

xidoreductases (Mqo)

-1.863

Q2FFA2

Uncharacterized leukocidin-like protein 2 (LukA)

-2.399

Q2FEP9

50S ribosomal protein L14 (RplN)

-2.437

A0A0H2XIJ3

Autolysin (Atl)

-3.000

Q2FGA5

tRNA-specific 2-thiouridylase MnmA (MnmA)

-3.199

A0A0H2XF07

Putative zinc-binding dehydrogenase (2317)

-3.208

A0A0H2XG28

Ribosome-binding ATPase (YchF)

-3.270

A0A0H2XHB4

Ribose-phosphate pyrophosphokinase (Prs)

-3.347

A0A0H2XGH4

Amidohydrolase family protein (2517)

-3.803

A0A0H2XKC5

ABC transporter, ATP-binding protein (0630)

-4.599

A0A0H2XG16

Clumping factor A (ClfA)

-4.737
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Table A-1. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XK08

Oxidoreductase, short chain dehydrogenase/reductase
family (2275)

-5.152

A0A0H2XI39

Uncharacterized protein (AmaP)

-6.056

A0A0H2XGT6

Alkyl hydroperoxide reductase (AhpD)

-9.383

A0A0H2XH45

Putative lipoprotein (SaeP)

-14.94

A0A0H2XHF0

Carboxylic ester hydrolase (PnbA)

-25.26
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Table A-2. Proteins Identified in Proteomic Analysis of Membrane Fraction

Protein ID

Gene

Fold
change

A0A0H2XJH7

Immunoglobulin G binding protein A (Spa)

21.72

A0A0H2XH66

Oligopeptide permease, peptide-binding protein (Opp1A)

21.27

Q2FE79

Immunoglobulin-binding protein (Sbi)

16.15

A0A0H2XKN2

Uncharacterized protein (pUSA10004)

15.73

A0A0H2XH62

D-lactate dehydrogenase (Ddh)

11.70

Q2FJH7

N-acetylmuramoyl-L-alanine amidase (Sle1)

9.924

A0A0H2XHT0

ABC transporter, ATP-binding protein (2453)

7.736

A0A0H2XIY3

HAD-superfamily hydrolase, subfamily IA, variant 1
(0557)

6.051

Q2FG29

Alanine dehydrogenase 2 (Ald2)

5.661

A0A0H2XKF0

Pyrimidine nucleoside transport protein (NupC)

5.530

A0A0H2XEB0

Iron compound ABC transporter, iron compound-binding
protein (HtsA)

3.883
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XHX1

Putative teichoic acid biosynthesis protein B (0247)

3.543

A0A0H2XJW8

Putative pyridoxal phosphate-dependent acyltransferase
(0535)

3.522

A0A0H2XHW1

ABC transporter ATP-binding protein (0620)

3.207

A0A0H2XFS4

Phosphoribosylamine—glycine ligase (PurD)

3.107

A0A0H2XJ90

D-isomer specific 2-hydroxyacid dehydrogenase family
protein (2496)

3.069

Q2FGI6

Probable glycine dehydrogenase (decarboxylating)
subunit 1 (GcvPA)

2.936

Q2FDW8

PTS system glucoside-specific EIICBA component
(GGlcB)

2.804

A0A0H2XFM4

Glucokinase (Glk)

2.404

Q2FEZ3

Pyrimidine-nucleoside phosphorylase (Pdp)

2.279

Q2FI17

Probable quinol oxidase subunit 2 (GoxA)

2.072

A0A0H2XGA6

L-lactate permease (2313)

2.021
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

Q2FDQ4

Fructose-bisphosphate aldolase class 1 (Fda)

1.874

A0A0H2XGF3

Dihydroxyacetone kinase, DhaK subunit (0636)

1.809

Q2FKC0

Phosphopentomutase (DeoB)

1.795

A0A0H2XHC2

Glutamate dehydrogenase (GudB)

1.760

Q2FDQ7

L-lactate dehydrogenase 2 (Idh2)

1.756

A0A0H2XHQ4

Alkyl hydroperoxide reductase, subunit F (AhpF)

1.743

A0A0H2XH50

1,4-dihydroxy-2-naphthoyl-CoA synthase (MenB)

1.564

A0A0H2XEF6

Purine nucleoside phosphorylase DeoD-type (DeoD)

1.521

Q2FJ87

Uncharacterized epimerase/dehydratase (0538)

1.505

A0A0H2XEI4

Transcription termination/antitermination protein (NusG)

-1.508

A0A0H2XG62

Uncharacterized protein (YfrA)

-1.509
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

Q2FG61

Trigger factor (Tig)

-1.614

Q2FJA2

50S ribosomal protein L1 (RplA)

-1.633

Q2FH25

2-oxoglutarate dehydrogenase E1 component (OdhA)

-1.668

A0A0H2XHD3

Uncharacterized protein (1729)

-1.685

Q2FEP2

50S ribosomal protein L2 (RplB)

-1.741

A0A0H2XGA1

Dehydrogenase family protein (2251)

-1.746

Q2FHM2

Methionyl-tRNA formyltransferase (FmtA)

-1.748

Q2FJA1

50S ribosomal protein L10 (RplJ)

-1.780

A0A0H2XG28

Ribosome-binding ATPase (YchF)

-1.860

Q2FEV0

Alkaline shock protein 23 (Asp23)

-1.863

Q2FJC3

Lysine--tRNA ligase (LysS)

-1.865
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XHC7

50S ribosomal protein L29 (RpmC)

-1.866

A0A0H2XFU7

Aldehyde dehydrogenase (AldA2)

-1.890

A0A0H2XJG5

Uncharacterized protein (2473)

-1.900

A0A0H2XKD0

Phosphoribosylaminoimidazole carboxylase, catalytic
subunit (PurE)

-1.913

Q2FF08

50S ribosomal protein L31 type B (RpmE2)

-2.108

Q2FF06

Putative aldehyde dehydrogenase (2076)

-2.127

Q2FEM9

Lipid II:glycine glycyltransferase (FemX)

-2.134

Q2FER6

50S ribosomal protein L17 (RplQ)

-2.138

A0A0H2XF85

UvrABC system protein A (UvrA)

-2.181

Q2FGD8

30S ribosomal protein S20 (RpsT)

-2.183

A0A0H2XHS5

Putative thioredoxin (0789)

-2.234
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

Q2FH99

Catalase (KatA)

-2.293

A0A0H2XH45

Putative lipoprotein (0693)

-2.399

A0A0H2XFR7

Chaperone protein (ClpB)

-2.469

A0A0H2XHR8

Uncharacterized protein (Pfpl)

-2.474

A0A0H2XGF4

Sodium:dicarboxylate symporter family protein (0382)

-2.505

A0A0H2XII5

Phosphotransferase system, fructose-specific IIABC
component (2576)

-2.534

A0A0H2XK77

Uncharacterized protein (SaeQ)

-2.559

Q2FK73

PTS system glucose-specific EIICBA component (PtsG)

-2.571

A0A0H2XFW6

Dihydroorotate dehydrogenase (quinone) (PyrD)

-2.627

Q2FEC8

Uncharacterized lipoprotein (2315)

-2.700

Q2FJP8

30S ribosomal protein S6 (RpsF)

-2.709
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XFG6

Uncharacterized protein (1698)

-2.737

A0A0H2XIS0

Uncharacterized protein (1230)

-2.963

A0A0H2XKH6

Universal stress protein family (0067)

-3.045

A0A0H2XI39

Uncharacterized protein (AmaP)

-3.080

Q2FGH0

Superoxide dismutase [Mn/Fe] 1 (SodA)

-3.282

A0A0H2XH82

Putative lipoprotein (0372)

-3.316

Q2FGZ4

Cell cycle protein GpsB (GpsB)

-3.506

Q2FIM4

Epimerase family protein (0753)

-3.727

A0A0H2XGC6

Lantibiotic epidermin immunity protein F (EpiF)

-4.203

Q2FDU6

Dehydrosqualene desaturase (CrtN)

-4.391

A0A0H2XGV7

Methicillin resistance protein (FemA)

-4.885

83

Table A-2. (Continued)

Protein ID

Gene

Fold
change

Q2FKI2

Probable copper-transporting P-type ATPase B (CopB)

-5.164

A0A0H2XKC5

ABC transporter, ATP-binding protein (AbcA)

-5.203

Q2FG56

Translation initiation factor IF-3 (InfC)

-5.245

A0A0H2XEN6

Putative membrane protein (1864)

-5.312

Q2FK70

PTS system EIIBC component (0194)

-5.354

A0A0H2XHQ0

Putative transcriptional regulator (2259)

-5.499

A0A0H2XJG9

Uncharacterized protein (1684)

-5.795

Q2FEI5

Putative formate dehydrogenase (2258)

-5.865

A0A0H2XI99

ESAT-6 secretion system extracellular protein A (EsxA)

-7.589

A0A0H2XG16

Clumping factor A (ClfA)

-7.919

A0A0H2XK60

Uncharacterized protein (0664)

-10.87
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Table A-2. (Continued)

Protein ID

Gene

Fold
change

A0A0H2XGT6

Alkyl hydroperoxide reductase (AhpD)

-13.40
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